<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>一种具有治疗潜力的非致幻剂迷幻剂类似物A non-hallucinogenic psychedelic analog with therapeutic potential</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">A non-hallucinogenic psychedelic analog with therapeutic potential<br/>一种具有治疗潜力的非致幻剂迷幻剂类似物</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2022-02-17 20:01:22</div><div class="page_narrow text-break page_content"><p>3Department of Molecular, Cell &amp; Developmental Biology, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA</p><p>3分子、细胞和分子生物学系；加利福尼亚大学发展生物学，圣克鲁斯，1156大街，圣克鲁斯，CA 95064，美国</p><p>   4Department of Neurology, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94143, USA</p><p>加利福尼亚大学神经病学系，旧金山，675 Nelson Rising Lane，旧金山，CA 94143，美国</p><p>     3Department of Molecular, Cell &amp; Developmental Biology, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA</p><p>3分子、细胞和分子生物学系；加利福尼亚大学发展生物学，圣克鲁斯，1156大街，圣克鲁斯，CA 95064，美国</p><p> 7Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, 1089 Veterinary Medicine Drive, Davis, CA 95616, USA</p><p>加利福尼亚大学动物医学院分子生物科学系，戴维斯，兽医学1089驱，戴维斯，CA 95616，美国</p><p> 8Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA</p><p>8威斯康星州医学院细胞生物学、神经生物学和解剖学系，地址：美国威斯康星州密尔沃基沃特敦普朗克路8701号，邮编：53226</p><p> 8Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA</p><p>8威斯康星州医学院细胞生物学、神经生物学和解剖学系，地址：美国威斯康星州密尔沃基沃特敦普朗克路8701号，邮编：53226</p><p>   9Department of Pharmacology, School of Medicine, University of California, Davis, 451 Health Sciences Drive, Suite 3503, Davis, CA 95616, USA</p><p>加利福尼亚大学医学院药理学系，戴维斯，451健康科学驾驶，套房3503，戴维斯，CA 95616，美国</p><p> 3Department of Molecular, Cell &amp; Developmental Biology, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA</p><p>3分子、细胞和分子生物学系；加利福尼亚大学发展生物学，圣克鲁斯，1156大街，圣克鲁斯，CA 95064，美国</p><p>  10West Coast Metabolomics Center, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA</p><p>加利福尼亚大学西海岸代谢组学中心，戴维斯，一个盾牌大道，戴维斯，CA 95616，美国</p><p> 10West Coast Metabolomics Center, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA</p><p>加利福尼亚大学西海岸代谢组学中心，戴维斯，一个盾牌大道，戴维斯，CA 95616，美国</p><p> 9Department of Pharmacology, School of Medicine, University of California, Davis, 451 Health Sciences Drive, Suite 3503, Davis, CA 95616, USA</p><p>加利福尼亚大学医学院药理学系，戴维斯，451健康科学驾驶，套房3503，戴维斯，CA 95616，美国</p><p> 8Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA</p><p>8威斯康星州医学院细胞生物学、神经生物学和解剖学系，地址：美国威斯康星州密尔沃基沃特敦普朗克路8701号，邮编：53226</p><p> 7Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, 1089 Veterinary Medicine Drive, Davis, CA 95616, USA</p><p>加利福尼亚大学动物医学院分子生物科学系，戴维斯，兽医学1089驱，戴维斯，CA 95616，美国</p><p>  4Department of Neurology, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94143, USA</p><p>加利福尼亚大学神经病学系，旧金山，675 Nelson Rising Lane，旧金山，CA 94143，美国</p><p>  3Department of Molecular, Cell &amp; Developmental Biology, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA</p><p>3分子、细胞和分子生物学系；加利福尼亚大学发展生物学，圣克鲁斯，1156大街，圣克鲁斯，CA 95064，美国</p><p> 14Department of Biochemistry &amp; Molecular Medicine, School of Medicine, University of California, Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, CA 95817, USA</p><p>14生物化学与化学系；分子医学，加利福尼亚大学医学院，戴维斯，2700斯托克顿BLVD，套房2102，萨克拉门托，CA 95817，美国</p><p> Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms</p><p>出于学术研究目的，用户可以查看、打印、复制和下载此类文件中的文本和数据挖掘内容，并始终遵守完整的使用条件：http://www.nature.com/authors/editorial_policies/license.html#terms</p><p>   The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals.   Unlike most substance use disorder (SUD) medications, anecdotal reports suggest that ibogaine possesses the potential to treat patients addicted to a variety of substances including opiates, alcohol, and psychostimulants. Like other psychedelic compounds, its therapeutic effects are long-lasting,   which has been attributed to its ability to modify addiction-related neural circuitry through activation of neurotrophic factor signaling.  ,  However, several safety concerns have hindered the clinical development of ibogaine including its toxicity, hallucinogenic potential, and proclivity for inducing cardiac arrhythmias. Here, we apply the principles of function-oriented synthesis (FOS) to identify the key structural elements of its potential therapeutic pharmacophore, enabling us to engineer tabernanthalog (TBG)—a water soluble, non-hallucinogenic, non-toxic analog of ibogaine that can be prepared in a single step. TBG promoted structural neural plasticity, reduced alcohol- and heroin-seeking behavior, and produced antidepressant-like effects in rodents. This work demonstrates that through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant with therapeutic potential.</p><p>迷幻生物碱伊博加因对人和动物都有抗成瘾作用。与大多数物质使用障碍（SUD）药物不同，坊间报道表明伊博加因具有治疗对各种物质上瘾的患者的潜力，包括阿片类药物、酒精和精神刺激剂。与其他迷幻化合物一样，其治疗效果持久，这归因于其通过激活神经营养因子信号来改变成瘾相关神经回路的能力，然而，一些安全问题阻碍了伊博加因的临床开发，包括其毒性、致幻潜能和诱发心律失常的倾向。在这里，我们应用功能导向合成（FOS）的原理来确定其潜在治疗药效团的关键结构元素，使我们能够设计出塔贝南他洛格（TBG）——一种水溶性、非致幻剂、无毒的伊波加因类似物，可以一步制备。TBG促进了结构神经可塑性，减少了酒精和海洛因寻求行为，并在啮齿类动物中产生了抗抑郁作用。这项工作表明，通过仔细的化学设计，有可能对迷幻化合物进行修饰，以产生一种更安全、无致幻剂、具有治疗潜力的变体。</p><p> psychedelic, psychoplastogen, neural plasticity, ibogaine, function-oriented synthesis, drug design, neuropsychiatric disorder, substance use disorder, addiction, alcohol use disorder, opioid use disorder, antidepressant, depression, serotonin, 5-HT2A receptor</p><p>迷幻剂、精神塑化剂、神经可塑性、伊波加因、功能导向合成、药物设计、神经精神障碍、物质使用障碍、成瘾、酒精使用障碍、阿片类药物使用障碍、抗抑郁剂、抑郁症、5-羟色胺、5-HT2A受体</p><p> Ibogaine is the most abundant of the numerous alkaloids produced by  Tabernanthe iboga,   and though it has not been tested in double-blind placebo-controlled clinical trials, anecdotal reports and open-label studies suggest that it can reduce symptoms of drug withdrawal, reduce drug cravings, and prevent relapse.  ,  Unfortunately, ibogaine suffers from major issues that severely limit its potential as a therapeutic. First, access to large quantities has been limited by overexploitation of the plant from which it is derived as well as the lack of a scalable, enantioselective, total synthesis.   Currently, there are only three synthetic routes to racemic ibogaine with longest linear sequences of 9–16 steps and overall yields ranging from 0.1–4.8%.   Second, ibogaine’s safety profile is unacceptable. From a physicochemical perspective, it is very non-polar, which leads to its accumulation in adipose tissue   and contributes to its known cardiotoxicity through inhibition of hERG potassium channels.   ,  Several deaths have been linked to ibogaine’s cardiotoxicity,  ,  and it produces long-lasting hallucinations (&gt; 24 h). While ibogaine was once sold in France as a medicine for treating neuropsychiatric diseases, it was removed from the market due to its adverse effects.</p><p>伊博加因是由虎斑草产生的众多生物碱中含量最丰富的一种，尽管它尚未在双盲安慰剂对照临床试验中进行试验，但坊间报道和开放标签研究表明，它可以减少药物戒断症状，减少药物渴求，并防止复发，不幸的是，伊博加因存在严重问题，严重限制了其作为治疗药物的潜力。首先，由于对其来源的植物的过度开发，以及缺乏可扩展的、对映选择性的全合成，限制了对大量化合物的获取。目前，只有三条合成外消旋伊博卡因的路线，最长的线性序列为9-16步，总收率为0.1-4.8%。其次，伊博加因的安全状况是不可接受的。从物理化学角度来看，它是非常非极性的，这导致其在脂肪组织中积累，并通过抑制hERG钾通道而导致其已知的心脏毒性，有几例死亡与伊博加因的心脏毒性有关，并且会产生长期的幻觉（&gt；24小时）。虽然伊博加因曾作为治疗神经精神疾病的药物在法国销售，但由于其不良反应，它已从市场上消失。</p><p> Though ibogaine’s exact mechanism of action has not yet been fully elucidated, evidence suggests that it might alter addiction-related circuitry by promoting neural plasticity. First, ibogaine has been shown to increase glial cell line-derived neurotrophic factor (GDNF) expression in the ventral tegmental area (VTA), and intra-VTA infusion of ibogaine reduces alcohol-seeking behavior in rodents.   A more recent study demonstrated that ibogaine impacts brain-derived neurotrophic factor (BDNF) and GDNF signaling in multiple brain regions implicated in the behavioural effects of addictive drugs.   Recently, we demonstrated that noribogaine, an active metabolite of ibogaine,   is a potent psychoplastogen   that increases cortical neuron dendritic arbor complexity.   Other psychoplastogens, such as lysergic acid diethylamide (LSD) and psilocin (the active metabolite of psilocybin) have also been shown in anecdotal and open-label studies to decrease drug use in the clinic, similar to ibogaine.   We hypothesize that the ability of psychoplastogens to promote structural and functional neural plasticity in addiction-related circuitry might explain their abilities to reduce drug-seeking behavior for weeks to months following a single administration. Moreover, by modifying neural circuitry rather than simply blocking the targets of a particular addictive substance, psychoplastogens like ibogaine could have the potential to be broadly applicable anti-addictive agents.</p><p>虽然伊博加因的确切作用机制尚未完全阐明，但有证据表明，它可能通过促进神经可塑性改变成瘾相关的回路。首先，伊博加因已被证明能增加腹侧被盖区（VTA）的胶质细胞源性神经营养因子（GDNF）表达，VTA内输注伊博加因可减少啮齿类动物的酒精寻求行为。最近的一项研究表明，依博加碱影响与成瘾性药物行为效应有关的多个脑区的脑源性神经营养因子（BDNF）和GDNF信号。最近，我们证明了去甲烟碱，一种烟碱的活性代谢物，是一种有效的精神塑化剂，可增加皮质神经元树突状突起的复杂性。其他精神塑化剂，如麦角酸二乙酰胺（LSD）和psilocin（psilocybin的活性代谢物），也已在轶事和开放标签研究中显示，可减少临床用药，类似于伊博加因。我们假设，精神塑化剂在成瘾相关回路中促进结构和功能神经可塑性的能力可能解释了它们在单次给药后数周到数月内减少药物寻求行为的能力。此外，通过改变神经回路而不是简单地阻断特定成瘾物质的靶点，像伊博加因这样的精神塑化剂可能具有广泛应用的抗成瘾剂的潜力。</p><p> In order to develop simplified, and potentially safer analogs, we first needed to understand which of ibogaine’s structural features were critical for its psychoplastogenic effects. Our approach mirrored that taken by Wender and colleagues in their seminal FOS studies on the structurally complex marine natural product bryostatin 1.   Here, we report our efforts to engineer simplified analogs of iboga alkaloids (ibogalogs) that lack ibogaine’s toxicity and hallucinogenic effects but maintain its behavioural effects in rodent models of drug self-administration and relapse.</p><p>为了开发简化的、潜在更安全的类似物，我们首先需要了解ibogaine的哪些结构特征对其心理塑形效应至关重要。我们的方法反映了Wender及其同事在对结构复杂的海洋天然产物bryostatin 1进行的开创性FOS研究中所采取的方法。在这里，我们报告了我们为设计伊博加生物碱（ibogalogs）的简化类似物所做的努力，这些类似物缺乏伊博加碱的毒性和致幻作用，但在药物自我给药和复发的啮齿类动物模型中保持其行为效应。</p><p> The hallmarks of ibogaine’s structure include an indole, a 7-membered tetrahydroazepine, and a bicyclic isoquinuclidine (  Fig. 1). We reasoned that systematic deletion of these key structural elements would reveal the essential features of ibogaine’s psychoplastogenic pharmacophore. By adapting chemistry developed by Sames and co-workers,   we were able to access a series of isoquinuclidine-containing compounds ( 8– 11) that lacked the tetrahydroazepine and/or indole characteristic of ibogaine (  Extended Data Fig. 1a). Ibogalog  8a lacks both the indole and tetrahydroazepine rings characteristic of ibogaine, while  9a– 11a only lack the tetrahydroazepine. Ibogamine, ibogaine, and noribogaine only differ from  9a,  10a, and  11a by the presence of the C2–C16 bond (LeMen and Taylor convention), respectively.</p><p>伊博加因结构的特征包括一种吲哚、一种七元四氢氮杂卓和一种双环异喹uclidine（图1）。我们推断，系统地删除这些关键结构元素将揭示伊博加因的精神塑形药效团的基本特征。通过调整Sames及其同事开发的化学，我们能够获得一系列含有异喹脲的化合物（8-11），这些化合物缺乏伊波加因的四氢氮卓和/或吲哚特征（扩展数据图1a）。Ibogalog 8a缺乏ibogaine所特有的吲哚环和四氢氮杂环，而9a–11a仅缺乏四氢氮杂环。Ibogamine、ibogaine和noribogaine仅因C2–C16键的存在而分别与9a、10a和11a不同（LeMen和Taylor约定）。</p><p> Except for  11a, ibogalogs containing the isoquinuclidine but lacking the tetrahydroazepine ring ( 8– 10 and  11b) were either weak psychoplastogens or did not promote neuronal growth compared to the vehicle (VEH) control (  Extended Data Fig. 2). In contrast, the majority of ibogalogs lacking the isoquinuclidine but retaining the tetrahydroazepine ( 12– 16) were efficacious (  Extended Data Fig. 2). Indole substitution at C5 with either fluorine ( 15) or chlorine ( 16) was tolerated, but a more sterically demanding bromine substituent ( 17) was not. We found that IBG ( 13) performed comparably to ibogaine despite having a simplified chemical structure. We prioritized IBG for further development as we reasoned that its reduced lipophilicity (cLogP = 2.61) relative to ibogaine (cLogP = 4.27) would make formulation less challenging and also reduce the potential for cardiotoxicity, as lipophilicity is a known contributing factor to hERG channel inhibition. The attractiveness of IBG as a potential therapeutic was underscored by its improved CNS multiparameter optimization (MPO) score   (IBG MPO = 5.2; Ibogaine MPO = 3.8; optimal MPO = 6.0) coupled with the fact that it can be synthesized in a single step.</p><p>除11a外，与载体（VEH）对照组相比，含有异喹uclidine但缺乏四氢氮杂卓环（8–10和11b）的ibogalogs要么是弱的精神塑化剂，要么没有促进神经元生长（扩展数据图2）。相比之下，大多数缺乏异喹uclidine但保留四氢氮杂卓（12-16）的ibogalogs是有效的（扩展数据图2）。C5上的吲哚可以被氟（15）或氯（16）取代，但对空间要求更高的溴取代基（17）则不行。我们发现，尽管IBG（13）具有简化的化学结构，但其表现与ibogaine相当。我们优先考虑IBG的进一步开发，因为我们认为其亲脂性（cLogP=2.61）相对于伊博加因（cLogP=4.27）的降低将降低配方的挑战性，并降低心脏毒性的可能性，因为亲脂性是已知的hERG通道抑制的促因。IBG作为一种潜在治疗药物的吸引力通过其改进的CNS多参数优化（MPO）评分（IBG MPO=5.2；Ibogaine MPO=3.8；optimal MPO=6.0）以及它可以在一步中合成的事实得到了强调。</p><p> Inspection of IBG’s structure reveals its similarity to the potent hallucinogen and 5-HT2A agonist 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT). Pioneering structure-activity relationship (SAR) studies conducted by Glennon and co-workers demonstrated that, unlike 5-MeO-DMT and other known hallucinogens, 6-MeO-DMT did not substitute for the hallucinogen 2,5-dimethoxy-4-methylamphetamine (DOM) at any dose in rodents trained to discriminate DOM from saline.   Moreover, our group has shown that 6-MeO-DMT does not produce a head-twitch response (HTR)  —a well-established rodent behavioral proxy for hallucinations induced by 5-HT2A agonists.   Therefore, we synthesized the 6-methoxyindole-fused tetrahydroazepine  18. As  18 resembles the iboga alkaloid tabernanthine, we refer to this compound as tabernanthalog (TBG). Like IBG, TBG can be synthesized in a single step enabling us to rapidly access large quantities (&gt;1 g).</p><p>对IBG结构的检查显示其与强效迷幻剂和5-HT2A激动剂5-甲氧基-N，N-二甲基色胺（5-MeO-DMT）相似。Glennon及其同事进行的开创性结构-活性关系（SAR）研究表明，与5-MeO-DMT和其他已知的致幻剂不同，6-MeO-DMT不能在任何剂量下替代致幻剂2,5-二甲氧基-4-甲基安非他明（DOM），用于训练啮齿类动物区分DOM和盐水。此外，我们的研究小组已经证明，6-MeO-DMT不会产生头部抽搐反应（HTR）——一种公认的啮齿动物行为替代物，用于5-HT2A激动剂诱导的幻觉。因此，我们合成了6-甲氧基吲哚-四氢氮杂卓18。由于18类似于伊博加生物碱塔伯南他林，我们称这种化合物为塔伯南他林（TBG）。与IBG一样，TBG可以在一个步骤中合成，使我们能够快速获得大量（&gt；1g）。</p><p> To evaluate the hallucinogenic potential of IBG and TBG, we tested them in the HTR assay using 5-MeO-DMT (10 mg/kg) as a positive control (  Fig. 2a). While 5-MeO-DMT produces a robust HTR, its conformationally restricted analog IBG exhibits significantly reduced hallucinogenic potential. As hypothesized, the 6-methoxy substituent of TBG rendered it devoid of hallucinogenic potential as measured by the HTR assay. For these in vivo studies, we used the fumarate salts of IBG and TBG. Unlike ibogaine hydrochloride, they are readily soluble in 0.9% saline up to 40 mg/mL (  Extended Data Table 1).</p><p>为了评估IBG和TBG的致幻潜能，我们在HTR试验中使用5-MeO-DMT（10 mg/kg）作为阳性对照对其进行了测试（图2a）。虽然5-MeO-DMT能产生稳定的HTR，但其构象受限的类似物IBG的致幻潜能显著降低。根据假设，TBG的6-甲氧基取代基使其没有HTR测定的致幻潜能。在这些体内研究中，我们使用了IBG和TBG的富马酸盐。与盐酸依博加因不同，它们易溶于0.9%的生理盐水，最高可达40 mg/mL（扩展数据表1）。</p><p>  The lipophilicity of ibogaine not only poses practical issues for its administration, it is likely a major factor contributing to its toxicity and adverse cardiac effects. Ibogaine inhibits hERG channels with an IC 50 of 1 μM (  Fig. 2b). In contrast, IBG and TBG are approximately 10- and 100-fold less potent than ibogaine, respectively, indicating a lower potential for cardiotoxicity. Administration of ibogaine to immobilized larval zebrafish decreased heart rate (  Extended Data 3a,  Video S1) and increased the likelihood for inducing arrhythmias as measured by the ratio of atrium to ventricle beats per minute (BPM) (  Fig. 2c). Neither IBG nor TBG induced these undesirable phenotypes.</p><p>伊博加因的亲脂性不仅给其给药带来了实际问题，而且可能是导致其毒性和不良心脏效应的主要因素。依博加因抑制hERG通道的IC50为1μM（图2b）。相比之下，IBG和TBG的效力分别比ibogaine低约10倍和100倍，表明心脏毒性的可能性较低。通过每分钟心房与心室搏动（BPM）的比率（图2c）测量，给固定化斑马鱼幼体服用伊博加因可降低心率（扩展数据3a，视频S1），并增加诱发心律失常的可能性。IBG和TBG均未诱导这些不良表型。</p><p> To compare the acute behavioral effects of ibogaine, IBG, and TBG, we treated larval zebrafish with these compounds across a range of doses (1–200 μM), recorded their behavioral responses to a battery of light and acoustic stimuli,  ,  and analyzed the resulting behavioral profiles (  Extended Data 3b). Treatment with ibogaine and noribogaine produced behavioral profiles similar to the lethal control (  Extended Data 3b–  c). In contrast, IBG- and TBG-treated zebrafish produced behavioral profiles more similar to the vehicle control. With increasing concentration, ibogaine, noribogaine, and the hERG inhibitors haloperidol, sertindole, and terfenadine become more phenotypically distinct from the vehicle control, while more closely resembling the lethal control (eugenol, 100 μM) (  Extended Data 3d). In contrast, IBG and TBG did not produce this phenotype.</p><p>为了比较ibogaine、IBG和TBG的急性行为效应，我们用这些化合物在一定剂量范围内（1-200μM）处理斑马鱼幼虫，记录它们对一系列光和声刺激的行为反应，并分析由此产生的行为特征（扩展数据3b）。依波加因和去甲依波加因治疗产生的行为特征与致死对照相似（扩展数据3b-c）。相比之下，IBG和TBG处理的斑马鱼产生的行为特征更类似于载体对照。随着浓度的增加，依波加因、去甲依波加因和hERG抑制剂氟哌啶醇、舍丁多尔和特非那定在表型上与溶媒对照组更为不同，同时与致死对照组（丁香酚，100μM）更为相似（扩展数据3d）。相反，IBG和TBG不产生这种表型。</p><p> As it is unclear whether or not ibogaine causes seizures at very high doses,  ,  we next used larval zebrafish expressing GCaMP5 to assess seizurogenic potential. Neither ibogaine nor TBG produced excessive neural activity as was observed following treatment with the known seizure-inducing compound pentylenetetrazole (PTZ) (  Extended Data 3e,  Video S2).</p><p>由于目前尚不清楚伊博加因是否会在非常高的剂量下引起癫痫发作，我们接下来使用表达GCaMP5的斑马鱼幼体来评估致痫潜能。伊博加因和TBG均未产生过度的神经活动，正如使用已知的癫痫诱导化合物戊四唑（PTZ）治疗后观察到的那样（扩展数据3e，视频S2）。</p><p> Finally, we compared the morphological effects of ibogaine, IBG, and TBG using a well-established zebrafish developmental toxicity assay.   Ibogaine (100 μM) significantly increased malformations and mortality at 2 and 5 days post-fertilization (dpf), respectively (  Fig. 2d–  e). At both timepoints, the proportion of viable to non-viable fish was significantly different from vehicle control (p &lt; 0.0001). Ibogaine-treated zebrafish suffered from numerous malformations. Noribogaine treatment resulted in greater survival, but the majority of zebrafish exhibited yolk sac and/or pericardial edemas. In contrast, both IBG and TBG treatments (100 μM) resulted in significantly fewer non-viable fish than ibogaine (p &lt; 0.0001 for ibogaine vs. IBG and ibogaine vs. TBG at both 2 and 5 dpf). Importantly, reducing the concentration of TBG from 100 to 66 μM resulted in a proportion of viable to non-viable fish that was statistically indistinguishable from vehicle control after 5 dpf (p = 0.3864,   Extended Data 3f).</p><p>最后，我们使用成熟的斑马鱼发育毒性试验比较了伊博加因、伊博加因和TBG的形态学效应。Ibogaine（100μM）分别显著增加了受精后2天和5天（dpf）的畸形和死亡率（图2d-e）。在这两个时间点，活鱼和非活鱼的比例与媒介物对照组显著不同（p&lt；0.0001）。伊博加因治疗过的斑马鱼患有多种畸形。诺利博加碱治疗可提高存活率，但大多数斑马鱼出现卵黄囊和/或心包水肿。相比之下，IBG和TBG处理（100μM）产生的非活性鱼明显少于伊博加因（在2和5 dpf下，伊博加因与IBG和伊博加因与TBG的p&lt；0.0001）。重要的是，将TBG的浓度从100μM降低到66μM会导致在5 dpf后，从统计学上无法区分活鱼和非活鱼的比例，这与溶媒对照（p=0.3864，扩展数据3f）是不可区分的。</p><p> To validate the targets of IBG and TBG, we performed a panel of serotonin (5-HT) and opioid receptor functional assays assessing canonical GPCR signaling. Unlike noribogaine, IBG and TBG showed weak or no opioid agonist activity (  Extended Data Figs. 4 and   ​ and5). 5). However, IBG and TBG demonstrated potent agonist activity at human (  Fig. 2f) and mouse 5-HT2A receptors (  Extended Data Fig. 4). Many 5-HT2A agonists, such as 5-MeO-DMT, are also agonists of 5-HT2B receptors, which can lead to cardiac valvulopathy.   In contrast, IBG and TBG act as antagonists at 5-HT2B receptors (  Fig. 2f). When profiled across the 5-HT receptorome, both IBG and TBG displayed more selective, and potentially safer profiles as compared to the less conformationally restricted 5-MeO-DMT (  Extended Data Figs. 4 and   ​ and5). 5). A full safety screen across 81 potential targets revealed that TBG exhibits high selectivity for 5-HT2 receptors (  Extended Data Table 2).</p><p>为了验证IBG和TBG的靶点，我们进行了一组5-羟色胺（5-HT）和阿片受体功能分析，以评估标准GPCR信号。与去甲博加因不同，IBG和TBG表现出弱或无阿片类激动剂活性（扩展数据图4和图4）​ 和5）。5). 然而，IBG和TBG在人类（图2f）和小鼠5-HT2A受体（扩展数据图4）上显示出强大的激动剂活性。许多5-HT2A激动剂，如5-MeO-DMT，也是5-HT2B受体的激动剂，可导致心脏瓣膜病。相反，IBG和TBG作为5-HT2B受体的拮抗剂（图2f）。与构象限制性较小的5-MeO-DMT相比，当在5-HT受体上进行分析时，IBG和TBG显示出更具选择性和潜在安全性的特征（扩展数据图4和图4）​ 和5）。5). 对81个潜在靶点进行的全面安全筛选显示，TBG对5-HT2受体具有高选择性（扩展数据表2）。</p><p> To determine if TBG has rewarding effects, we performed a conditioned place preference assay (CPP) in mice (  Extended Data Fig. 6). A low dose of TBG (1 mg/kg) did not have any effect on place preference (p = 0.8972). Higher doses produced a modest conditioned place aversion (CPA) (p = 0.0199 for 10 mg/kg; p = 0.0489 for 50 mg/kg), suggesting that TBG has a low potential for abuse.</p><p>为了确定TBG是否具有奖励效应，我们在小鼠中进行了条件位置偏爱试验（CPP）（扩展数据图6）。低剂量TBG（1 mg/kg）对位置偏好没有任何影响（p=0.8972）。高剂量会产生适度的条件性位置厌恶（CPA）（对于10 mg/kg，p=0.0199；对于50 mg/kg，p=0.0489），表明TBG滥用的可能性较低。</p><p> Having demonstrated the improved safety profile of TBG relative to ibogaine, we next assessed its effects on structural plasticity. Treating rat embryonic cortical neurons with TBG increased dendritic arbor complexity as measured by Sholl analysis (  Fig. 3a), and this effect appears to be 5-HT2A-dependent, as it was blocked by pretreatment with the 5-HT2A antagonist ketanserin (  Fig. 3b).</p><p>在证明了TBG相对于ibogaine的安全性改善后，我们接下来评估了其对结构塑性的影响。通过Sholl分析（图3a），用TBG处理大鼠胚胎皮层神经元增加了树突状树枝的复杂性，这种效应似乎是5-HT2A依赖性的，因为它被5-HT2A拮抗剂酮色林预处理阻断（图3b）。</p><p>  In addition to promoting dendritic growth, TBG also increases dendritic spine density to a comparable extent as ibogaine in mature cortical cultures (DIV20) (  Fig. 3c–  d). Next, we used transcranial 2-photon imaging (  Fig. 3e) to assess the effects of TBG on spine dynamics in mouse sensory cortex. Both TBG and the hallucinogenic 5-HT2A agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) increased spine formation without impacting spine elimination 24 h after treatment (  Fig. 3f–  g). Similar results were observed in more anterior parts of the cortex and mirrored the effects of ketamine reported previously.</p><p>除了促进树突生长外，TBG还增加树突棘密度，其程度与成熟皮层培养中的依博加碱相当（图3c-d）。接下来，我们使用经颅双光子成像（图3e）来评估TBG对小鼠感觉皮层脊柱动力学的影响。治疗24小时后，TBG和致幻5-HT2A激动剂2,5-二甲氧基-4-碘安非他明（DOI）均增加了脊柱形成，但不影响脊柱消除（图3f-g）。在更多的皮质前部也观察到了类似的结果，反映了之前报道的氯胺酮的作用。</p><p> As increased structural plasticity in the anterior parts of the brain (e.g. prefrontal cortex, PFC) have been shown to mediate the sustained (&gt;24 h) antidepressant-like effects of ketamine   in rodent models and are hypothesized to play a key role in the therapeutic effects of 5-HT2A agonists,  ,  we next evaluated the impact of TBG on forced swim test (FST) behavior following 7 days of unpredictable mild stress (UMS) (  Extended Data Fig. 7a–  b) in mice. Immobility time was significantly increased after UMS. This effect was rescued by a 50 mg/kg, but not 10 mg/kg, dose of TBG. Preliminary pharmacokinetic studies revealed that a 50 mg/kg dose of TBG produced significantly higher brain concentrations than did a 10 mg/kg dose (  Extended Data Fig. 7c). Therefore, the 50 mg/kg dose was used in subsequent mouse behavioral experiments.</p><p>随着大脑前部（如前额叶皮质，PFC）结构可塑性的增加，已被证明在啮齿动物模型中介导氯胺酮的持续（&gt；24小时）抗抑郁样作用，并被假设在5-HT2A激动剂的治疗效果中起关键作用，接下来，我们评估了TBG对小鼠在7天不可预测轻度应激（UMS）后强迫游泳试验（FST）行为的影响（扩展数据图7a-b）。UMS后的不动时间显著增加。这种效应通过50mg/kg（而非10mg/kg）剂量的TBG得以缓解。初步药代动力学研究显示，50mg/kg剂量的TBG产生的大脑浓度明显高于10mg/kg剂量（扩展数据图7c）。因此，在随后的小鼠行为实验中使用了50 mg/kg剂量。</p><p> As ketamine produces antidepressant-like effects in the FST even in the absence of UMS, we performed a head-to-head comparison with TBG in this experiment (  Fig. 4a–  b). Drugs were administered 24 h after a pre-test, and the FST was performed 24 h and 7 d post drug administration. Both ketamine and TBG significantly reduced immobility in mice 24 h following drug administration, however, ketamine’s effects appeared to be more durable. Importantly, TBG had no effect on locomotion 24 h following administration (  Extended Data Fig. 6c). As anticipated, treatment with a 5-HT2A antagonist (ketanserin) blocked the antidepressant-like effect of TBG (  Fig. 4b). The efficacy exhibited by TBG in the FST is consistent with the fact that other 5-HT2A agonists have demonstrated potential for treating depression.  ,  However, future studies should evaluate the effects of TBG on other behaviors relevant to depression, particularly those measuring anhedonia.</p><p>由于氯胺酮即使在没有UMS的情况下也会在FST中产生抗抑郁剂样作用，因此我们在本实验中与TBG进行了头对头比较（图4a-b）。在预试验后24小时给药，并在给药后24小时和7天进行FST。氯胺酮和TBG均能显著降低给药后24小时小鼠的不动性，但氯胺酮的作用似乎更持久。重要的是，给药后24小时，TBG对运动没有影响（扩展数据图6c）。正如预期的那样，用5-HT2A拮抗剂（酮西林）治疗可阻断TBG的抗抑郁样作用（图4b）。TBG在FST中表现出的疗效与其他5-HT2A激动剂已显示出治疗抑郁症的潜力的事实一致，然而，未来的研究应该评估TBG对其他与抑郁症相关的行为的影响，尤其是那些测量快感缺失的行为。</p><p> To assess the effect of TBG on alcohol (EtOH) intake, we employed an intermittent access 2-bottle choice (20% EtOH (v/v) vs. H 2O) experiment that models binge drinking behavior in humans.   Mice were subjected to repeated cycles of binge drinking and withdrawal over the course of 7 weeks (  Fig. 4c), which resulted in high EtOH consumption (11.44 ± 0.76 g/kg/24h), binge drinking-like behavior (3.89 ± 0.33 g/kg/4h), and generated blood alcohol content equivalent to that of human subjects suffering from alcohol use disorder (AUD). Systemic injections of TBG 3 h prior to a drinking session reduced binge drinking during the first 4 h without affecting water intake (  Fig. 4d). Consumption of alcohol was lower for at least two days following TBG administration (  Fig. 4e). Similar results were observed previously for ibogaine.   Importantly, administration of TBG prior to giving mice access to both water and a 5% sucrose solution did not decrease sucrose preference (  Fig. 4f) or total fluid consumption (  Fig. 4g), indicating that TBG selectively reduced alcohol intake.</p><p>为了评估TBG对酒精（EtOH）摄入量的影响，我们采用了一项间歇性两瓶选择（20%EtOH（v/v）vs.H2O）实验，模拟人类的狂饮行为。小鼠在7周的时间内反复进行暴饮暴食和戒断循环（图4c），导致高EtOH消耗（11.44±0.76 g/kg/24小时）、暴饮样行为（3.89±0.33 g/kg/4h），并产生与患有酒精使用障碍（AUD）的人类受试者相当的血液酒精含量。饮酒前3小时全身注射TBG可减少前4小时的暴饮暴食，但不影响饮水量（图4d）。TBG给药后至少两天内酒精消耗量较低（图4e）。之前观察到的伊博加因也有类似的结果。重要的是，在给小鼠提供水和5%蔗糖溶液之前，给予TBG不会减少蔗糖偏好（图4f）或总液体消耗量（图4g），这表明TBG选择性地减少了酒精摄入。</p><p> As with alcohol consumption, anecdotal reports suggest that ibogaine can reduce opioid use in humans.  ,  In rodent models of opioid self-administration, ibogaine produces the greatest decrease when administered at a dose of 40 mg/kg.   Here, we used a rat model of heroin self-administration (  Fig. 4h) to assess the effects of TBG (40 mg/kg) administered during three distinct epochs—during self-administration (SA), prior to the first day of extinction (EXT), and immediately before cued reinstatement (CUE). Vehicle was administered at these same time points whenever TBG was not (  Fig. 4i). Thus, each group received a total of 3 injections. When administered during self-administration (  Fig. 4j–  k), immediately prior to extinction (EXT,   Fig. 4l) or before cued rei</p><p>与饮酒一样，坊间报道表明伊博加因可以减少人类对阿片类药物的使用，在类阿片自我给药的啮齿类动物模型中，以40 mg/kg的剂量给药时，伊博加因产生最大的减少。在这里，我们使用海洛因自我给药的大鼠模型（图4h）来评估在自我给药（SA）、灭绝第一天（EXT）之前和线索恢复（CUE）之前的三个不同时期给予TBG（40 mg/kg）的效果。每当TBG不在时，就在这些相同的时间点给药（图4i）。因此，每组共接受3次注射。当在自我给药期间（图4j-k）、灭绝前（EXT，图4l）或提示rei前给药时</p><p>......</p><p>......</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/治疗/">#治疗</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/tbg/">#tbg</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>